BSBE(SZ:300406) Zheng Quan Zhi Xing·2025-07-25 16:14Core Viewpoint - The report outlines the key details regarding the issuance and management of the convertible bonds by Beijing Jiukang Biotechnology Co., Ltd., including the bond's characteristics, issuance approval, and adjustments to the conversion price due to stock repurchase and dividend distributions [3][4][10]. Group 1: Bond Issuance Details - The total issuance amount of the convertible bonds is RMB 1.139 billion, with a total of 11,390,000 bonds issued at a face value of RMB 100 each [4][5]. - The bond has a maturity period of 6 years, starting from June 30, 2022, to June 29, 2028 [5]. - The interest rates for the bond are structured to increase over the years, starting from 0.3% in the first year to 3.0% in the sixth year [5][6]. Group 2: Conversion Price Adjustments - The initial conversion price of the bonds was set at RMB 17.63 per share, which was adjusted to RMB 17.53 following a cash dividend distribution [12]. - Subsequent adjustments to the conversion price were made, bringing it down to RMB 17.55 after a stock repurchase and further to RMB 17.35 after another dividend distribution [14][16]. - The latest adjustment resulted in a conversion price of RMB 16.98, effective from July 23, 2025, due to additional stock repurchases [20]. Group 3: Credit Rating and Management - The bonds have been rated AA- by Zhongzheng Pengyuan Credit Rating Co., Ltd., with a stable outlook [15]. - The management of the bonds is overseen by China International Capital Corporation, which is responsible for ensuring the protection of bondholders' interests [20].